COSMOS Pharmaceutical Corporation
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 10 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/13 | ¥117.37 | ¥- | - |
| 2026/04/13 | ¥100.69 | ¥102.19 | +1.5% |
| 2026/01/13 | ¥84.01 | ¥81.73 | -2.7% |
| 2025/10/14 | ¥112.02 | ¥103.10 | -8.0% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
546.4K | 0.00% | |
|
VANGUARD HORIZON FUNDS-Vanguard Global Equity Fund
|
451.2K | -7.29% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
367.8K | +0.71% | |
|
Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund
|
356.3K | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
259.2K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
231.1K | +2.52% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Legato Capital Management LLC
|
6.8K | 0.00% |
Dividend History
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥45 | -40.7% |
| 2025 | ¥75 | +20.0% |
| 2024 | ¥63 | +6.4% |
| 2023 | ¥59 | +42.4% |
| 2022 | ¥41 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥755,414M | ¥827,697M | ¥964,989M | ¥1,011,390M |
| Gross Profit | ¥151,447M | ¥168,718M | ¥188,305M | ¥213,281M |
| Operating Income | ¥29,796M | ¥30,129M | ¥31,501M | ¥40,404M |
| Pretax Income | ¥33,100M | ¥32,824M | ¥33,818M | ¥42,626M |
| Net Income | ¥23,155M | ¥23,797M | ¥24,454M | ¥30,978M |
| EPS | ¥292.38 | ¥300.48 | ¥308.61 | - |
| Operating Margin | 3.94% | 3.64% | 3.26% | 3.99% |
| Balance Sheet | ||||
| Total Assets | ¥363,052M | ¥420,967M | ¥476,546M | ¥524,755M |
| Total Equity | ¥190,506M | ¥211,071M | ¥231,440M | ¥257,462M |
| Total Liabilities | ¥172,546M | ¥209,896M | ¥245,106M | ¥267,293M |
| Cash | ¥37,362M | ¥45,928M | ¥52,301M | ¥57,038M |
| Interest-bearing Debt | ¥9,413M | ¥18,201M | ¥34,063M | ¥49,957M |
| Equity Ratio | 52.47% | 50.14% | 48.57% | 49.06% |
| D/E Ratio | 0.05 | 0.09 | 0.15 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥32,194M | ¥54,434M | ¥55,175M | ¥52,467M |
| Investing CF | -¥43,717M | -¥49,113M | -¥57,329M | -¥55,448M |
| Financing CF | -¥6,222M | ¥3,245M | ¥8,527M | ¥7,717M |
| Free CF | -¥11,303M | ¥7,798M | -¥635M | -¥859M |
| Efficiency | ||||
| ROE | 12.15% | 11.27% | 10.57% | 12.03% |
| ROA | 6.38% | 5.65% | 5.13% | 5.90% |
Latest IR Information
-
Regarding the Concept and Policy for Reducing the Investment Unit
Disclosure outlining the policy to reduce the investment unit. Will carefully consider overall factors such as future performance, stock price levels, shareholder composition, and liquidity. If unclear, it is noted as 'Unknown'.
Read more -
Notice of Director Candidate Decision and Executive Changes
Decides on director candidates and discloses the names, appointments, and resignations of director candidates. Background information on the new candidate is provided, with formal decisions expected at the 44th ordinary general meeting of shareholders to be held on August 28,...
Read more -
【Cosmos Pharmaceutical】2026 Financial Results | Sales of ¥1,009.9 billion (YoY 8.7% increase)
Cosmos Pharmaceutical achieved sales of ¥1,009.9 billion (up 8.7% YoY) and operating profit of ¥4.253 billion (up 4.8%) for the fiscal year ending May 2026. The company expanded its store network and closed some stores, increasing net assets to ¥283.7...
Read more -
【Cosmos Pharmaceutical Co., Ltd.】Dividend increased to 44.5 yen | FY2026 May
Cosmos Pharmaceutical Co., Ltd. has approved an increase in the year-end dividend to 44.5 yen for FY2026, bringing the total annual dividend to 82 yen. The dividend will be paid out from retained earnings, effective August 10, 2026.
Read more -
FY2026 May Q3 Financial Summary [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending May 2026, net sales were JPY 810,380 million (7.7% YoY increase), operating income was JPY 32,021 million (1.2% YoY increase), and net income attributable to owners of parent for the quarter...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥7,620
Rating Score: 2.10 (Based on 10 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
COSMOS Pharmaceutical Corporation engages in the retail sale of pharmaceuticals, cosmetics, daily necessities, and food products in Japan. The company offers general medicines, energy drinks, oral and nursing care products, vitamins, health foods, diet foods, and prescriptions; and hair care and bath products. It also provides baby products, detergents, insect repellents, air fresheners, bath and toilet products, cooking supplies, gardening supplies, household and cleaning supplies, and clothing; processed foods, daily necessities, seasonings, confectionery, beverages, and alcohol; and tobacco and other products. In addition, the company engages in the maintenance and management of buildings and commercial facilities, traffic control, and security contracting activities. It sells its products through retail stores and online. COSMOS Pharmaceutical Corporation was incorporated in 1983 and is headquartered in Fukuoka City, Japan.
